Immutep has told investors it will go back to making eftilagimod alfa at the smaller scale used in its earlier studies. A review of the failed TACTI-004 trial found subtle structural differences in the drug used in that study.
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 Australian Biotech
Latest Video
New Stories
-
Government turns again to cheaper medicines as Guild eyes co-payment freeze
November 19, 2026 - - Latest News -
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

